menu
    • menu

    Company profile for Cellares

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to meet the total patient demand for cell therapies globally.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CellaresUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    345 Allerton Ave, South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cellares.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cellares-corporation/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cabaletta Bio, Cellares Ink 10-Year Supply Deal For Rese-Cel
    Cabaletta Bio, Cellares Ink 10-Year Supply Deal For Rese-Cel

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282575/0/en/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Cabaletta Bio Doses First Patients with Rese-cel from Cellares
    Cabaletta Bio Doses First Patients with Rese-cel from Cellares

    14 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-14/first-patients-dosed-with-cabaletta-bio-s-rese-cel-manufactured-on-cellares-automated-cell-shuttle

    PHARMIWEB
    14 Apr 2026
    Share Share
    Cellares, UW Expand CRISPR CAR-T Partnership
    Cellares, UW Expand CRISPR CAR-T Partnership

    18 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260218811269/en/Cellares-and-University-of-Wisconsin-School-of-Medicine-and-Public-Health-Expand-Partnership-to-Clinical-Manufacturing-of-CRISPR-Edited-CAR-T-for-Solid-Tumors

    BUSINESSWIRE
    18 Feb 2026
    Share Share
    Cellares Expands Automation for Gene-Edited Stem Cell Therapies
    Cellares Expands Automation for Gene-Edited Stem Cell Therapies

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260203174824/en/Cellares-to-Expand-Automated-Manufacturing-to-Gene-Edited-Stem-Cell-Therapies

    BUSINESSWIRE
    03 Feb 2026
    Share Share
    Cellares Attracts $257M Series D To Build Sites In Japan, Europe
    Cellares Attracts $257M Series D To Build Sites In Japan, Europe

    28 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/cellares-series-d-round-draws-257m-it-readies-commercial-production

    FIERCE PHARMA
    28 Jan 2026
    Share Share
    Cabaletta Bio Clears IND Amendment For Rese-Cel Manufacturing
    Cabaletta Bio Clears IND Amendment For Rese-Cel Manufacturing

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/ind-amendment-clearance-obtained-for-clinical-manufacturing-of-rese-cel-from-cabaletta-bio-using-cel

    PHARMIWEB
    12 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search